期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Phenobarbital Use as Adjunct to Benzodiazepines in the Treatment of Severe Alcohol Withdrawal Syndrome
1
作者 Cristina Roman Sibusisiwe Gumbo Kevin Okuni 《Journal of Pharmacy and Pharmacology》 2014年第9期551-557,共7页
Severe AWS (alcohol withdrawal syndrome) and AWD (alcohol withdrawal associated delirium) are common indications for intensive care unit admissions. Approximately 25% of patients with severe alcohol withdrawal req... Severe AWS (alcohol withdrawal syndrome) and AWD (alcohol withdrawal associated delirium) are common indications for intensive care unit admissions. Approximately 25% of patients with severe alcohol withdrawal require prolonged critical care hospital courses, often complicated by respiratory failure, need for mechanical ventilation due to administration of sedative continuous infusions and development of nosocomial infections. Although benzodiazepines are the mainstay of therapy for alcohol withdrawal, some patients exhibit benzodiazepine-refractory alcohol withdrawal. The use of phenobarbital as adjunct to benzodiazepines has been shown in studies to be effective in enhancing therapeutic responsiveness to benzodiazepines and reducing the need for mechanical ventilation. The objective of this study is to evaluate whether severe alcohol withdrawal treatment based on combining symptom-triggered benzodiazepine therapy with adjunctive phenobarbital will result in decreased mechanical ventilation rates, decreased use of continuous sedative infusions, decreased time to withdrawal symptom resolution and decreased length of stay in the intensive care unit. Chart reviews were utilized to determine total amount of benzodiazepine and phenobarbital use, need for mechanical ventilation, requirement of continuous lorazepam, dexmedetomidine or propofol infusions, average intensive care unit length of stay and incidence of adverse effects. 展开更多
关键词 Clinical institute withdrawal assessment of alcohol scale alcohol withdrawal syndrome DEXMEDETOMIDINE intensive care PHENOBARBITAL lorazepam.
下载PDF
Research progress on benzodiazepines to treat alcohol withdrawal syndrome
2
作者 Tiankai Jiang Yuhang Liang +3 位作者 Lan Jiang Yinhang Li Tiantian Jiang Ye Ruan 《Journal of Translational Neuroscience》 2022年第4期12-16,共5页
Alcohol withdrawal syndrome(AWS)refers to a series of symptoms and signs that chronic al-coholics experience when they suddenly stop drinking or reduce their drinking,usually 12 to 24 h later.These in-clude tremors,fa... Alcohol withdrawal syndrome(AWS)refers to a series of symptoms and signs that chronic al-coholics experience when they suddenly stop drinking or reduce their drinking,usually 12 to 24 h later.These in-clude tremors,fatigue,sweating,hyperreflexia,and gas-trointestinal symptoms.This article will analyze the drug treatment of this disease and make a brief review. 展开更多
关键词 alcohol withdrawal syndrome(AWS) benzodiazepine(BDZ) symptom-triggered regimens
下载PDF
Phenobarbital in the treatment of alcohol withdrawal syndrome
3
作者 Tiankai Jiang Lan Jiang +3 位作者 Yinhang Li Yuhang Liang Tiantian Jiang Hongyan Liu 《Journal of Translational Neuroscience》 2022年第4期7-11,共5页
Alcohol withdrawal syndrome(AWS)is a serious disorder affecting alcohol-dependent patients who abruptly stop or reduce their drinking.Mild or moderate AWS usually appears within 6 to 24 h after the last drink,and symp... Alcohol withdrawal syndrome(AWS)is a serious disorder affecting alcohol-dependent patients who abruptly stop or reduce their drinking.Mild or moderate AWS usually appears within 6 to 24 h after the last drink,and symptoms may include increased blood pressure and rapid pulse,tremors,high fever,irritability,anxiety,headache,nausea,and vomiting.These symptoms may progress to a more severe AWS characterized by delirium tremens,seizures,coma,cardiac arrest,and death.This article will analyze the phenobarbital(PB)treatment of AWS and make a brief review'. 展开更多
关键词 alcohol withdrawal syndrome(AWS) benzodiazepine(BDZ) phenobarbital(PB)
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部